title: The burden of prevention: downstream consequences of Pap smear testing in the elderly.
abstract: BACKGROUND
  Although cervical cancer is an unusual cause of death among women 65 and older, most elderly women in the US report continuing to undergo periodic Pap smear screening.
  
  
  OBJECTIVE
  To describe the incidence of Pap smears and downstream testing among elderly women.
  
  
  METHODS
  Claims-based analysis of female Medicare enrollees age 65 and older.
  
  
  METHODS
  Using three years of Medicare Part B 5% Files (1995-1997), we differentiated between women undergoing screening Pap smears and those undergoing Pap smears for surveillance of previous abnormalities or Pap smear follow-up. We determined the proportion of elderly women undergoing Pap smear testing and rates of downstream testing and procedures after an initial Pap smear.
  
  
  RESULTS
  Four million female Medicare beneficiaries over 65 years underwent Pap smear testing between 1995 and 1997, representing 25% of the eligible population. After adjusting for underbilling for Pap smears under Medicare, 43% of women over 65 are estimated to have undergone Pap smear testing during the 3-year period. The large majority (90%) of Pap smears were for screening, while 10% were done for surveillance or follow-up. For every 1000 women with a screening Pap smear, 39 had at least one downstream intervention within eight months of the initial Pap smear, including seven women who underwent colposcopy and two women who had other surgical procedures. Rates of downstream interventions were considerably higher for women undergoing Pap smear follow-up (302 per 1000 with at least one downstream intervention), and surveillance of previous abnormalities (209 per 1000 with a downstream intervention).
  
  
  CONCLUSIONS
  Cervical cancer screening is widespread among elderly American women, and follow-up testing is not uncommon, particularly among the ten percent of women who appear to be in a cycle of repeated testing. This substantial volume of testing occurs despite the rarity of cervical cancer deaths and unknown benefits of screening in this age group.
authors.affiliation: White River Junction VA Hospital, Vermont, and Dartmouth Medical School, Hanover, New Hampshire, USA. brenda.sirovich@dartmouth.edu
authors.forename: B E
authors.initials: BE
authors.lastname: Sirovich
authors.forename: D J
authors.initials: DJ
authors.lastname: Gottlieb
authors.forename: E S
authors.initials: ES
authors.lastname: Fisher
mesh_terms: D000368:Aged; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy / Q000706:statistics & numerical data; D006278:Medicare; D065006:Papanicolaou Test; D011315:Preventive Medicine / Q000592:standards*; D015203:Reproducibility of Results; D014481:United States; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000601:surgery; D014626:Vaginal Smears / Q000592:standards* / Q000706:statistics & numerical data